Clinical Trial Update: A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating treatment success when switching patients with schizophrenia or psychotic disorders from oral olanzapine to the long-acting injectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)
• Zyprexa (olanzapine)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Schizophrenia, Psychotic Disorders | Phase 4 | Status: COMPLETED